Study #2019-0618
Phase II Study of Dual Targeting of BCR-ABL1 by adding the Allosteric Inhibitor ABL001 in Patients with Chronic Myeloid Leukemia (CML) and Minimal Residual Disease (MRD) While on Therapy with Tyrosine Kinase Inhibitors
MD Anderson Study Status
Not Accepting
Treatment Agent
Asciminib
Description
This phase II trial studies how well ABL001 works in treating patients with chronic myeloid leukemia who are on therapy with tyrosine kinase inhibitor. ABL001 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving ABL001 and tyrosine kinase inhibitor together may work better than tyrosine kinase inhibitor alone in treating patients with chronic myeloid leukemia.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia
Study phase:
Phase II
Physician name:
Ghayas Issa
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.